Compare IPDN & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPDN | HSCS |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 7.5M |
| IPO Year | 2013 | 2022 |
| Metric | IPDN | HSCS |
|---|---|---|
| Price | $1.60 | $2.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.20 |
| AVG Volume (30 Days) | 49.9K | ★ 67.8K |
| Earning Date | 11-14-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,497,046.00 | $8,669.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.97 | $2.01 |
| 52 Week High | $12.39 | $6.47 |
| Indicator | IPDN | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 33.40 | 38.17 |
| Support Level | $1.55 | $2.16 |
| Resistance Level | $1.95 | $2.83 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 12.50 | 13.69 |
Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates majority of its revenue from TalentAlly Network Segment.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.